EU Medical Device Regulation Quiz

NameEmailPhone Number

1. According to the EU Medical Device Regulation (MDR 2017/745), which of the following best defines a medical device?

a) Any product used exclusively for cosmetic purposes

b) Equipment that only includes active implantable devices

c) Any instrument, apparatus, appliance, software, material, or similar, intended by the manufacturer to be used for human beings for specific medical purposes such as diagnosis, prevention, monitoring, treatment, or alleviation of disease or injury, which does not achieve its principal intended action by pharmacological, immunological, or metabolic means

d) Only invasive devices that contact internal tissues or organs

e) Any device that is used in hospitals

2. Which of the following products is newly regulated under the MDR, despite not having an intended medical purpose?

a) An in vitro diagnostic test for infectious diseases

b) A pacemaker for cardiac rhythm management

c) Colored contact lenses used solely for cosmetic purposes

d) A wheelchair for mobility assistance

e) Massager with pain-relieving claim

3. What is the primary role of a Notified Body under the EU MDR?

a) To manufacture and distribute medical devices in the EU

b) To evaluate the conformity of certain medical devices, perform audits, and issue certification to ensure they meet essential safety and performance requirements

c) To market and promote medical devices within the EU

d) To replace the manufacturer's responsibility for clinical evaluation

e) To handle post-market surveillance and incident reporting exclusively

4. What is the main role of EUDAMED under the MDR?

a) To directly approve medical devices for market access

b) To replace the Notified Body certification process entirely

c) To handle only the clinical evaluation data for devices

d) To serve as a centralized database for storing and sharing registration, conformity, vigilance, and post-market data related to medical devices

e) To act as a platform solely for manufacturers to submit marketing applications

5. Which of the following is an explicit requirement for manufacturers regarding vigilance?

a) Manufacturers must report any incident involving a device within 30 days, regardless of severity

b) Manufacturers must report serious incidents and field safety corrective actions to the competent authority via EUDAMED

c) Manufacturers are only required to report incidents if requested by the notified body

d) Manufacturers must report all incidents directly to the Competent Authority

e) Manufacturers must report all incidents directly to the European Commission

6. Which of the following is not considered an economic operator under the EU MDR?

a) The manufacturer of the medical device

b) The authorized representative

c) The importer

d) The healthcare professional using the device in a hospital

e) The distributor responsible for supplying the device in the supply chain

7. Which of the following is NOT a mandatory element to be included in the DoC according to MDR? (Annex IV)

a) Basic UDI-DI

b) Instructions for use

c) Name and address of the manufacturer

d) Risk class of the device

e) All of the above

8. Which of the following items is not required to be included in the EU Medical Device Declaration of Conformity (DoC)?

a) The manufacturer's name and address

b) A list of all clinical investigations conducted

c) The applicable EU directives and standards referenced

d) A clear statement of conformity to the relevant requirements

e) The device's identification and model number

9. Which of the following is considered as a software as medical device (SaMD) under MDR?

a) A fitness tracking app to monitor physical activity

b) Firmware embedded in an insulin pump that controls the delivery of insulin based on real-time glucose readings

c) Software integrated into an ultrasound machine that processes sound waves to generate real-time images of a fetus or internal organs for diagnostic purposes

d) A mobile app for providing diagnostic information to healthcare professionals

e) Bluetooth software

10. How many risk classes of devices are classified in the MDR Classification Rule? (Chapter 5: Article 51, 1)

a) 1

b) 2

c) 3

d) 4

e) 5

11. What factors determine the classification of a medical device under MDR?

a) Based on its mode of operation, such as duration of use, and whether it interacts with the human body

b) Based on its intended purpose and inherent risk

c) Based on its complexity of the device's design, such as materials and manufacturing process

d) Based on its potential to replace existing medical technologies

e) Based on the conformity route chosen

12. Which of the following is not the specific medical purposes for which a medical device can be intended? (Chapter I: Article 2)

a) providing information by means of in vitro examination of specimens derived from the human body, including organ, blood and tissue donations

b) diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury or disability

c) diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease

d) Monitoring the level of environmental allergens in a hospital to prevent patient exposure

e) investigation, replacement or modification of the anatomy or of a physiological or pathological process or state

13. Which of the following best describes the differences between the requirements for custom-made devices and regular medical devices under the MDR?

a) Custom-made devices require a "Statement for Custom-made Devices" to be issued by the manufacturer, while regular devices require a Declaration of Conformity (DoC)

b) Custom-made devices are exempt from requiring clinical evaluation reports, unlike regular devices, which must include these as part of their technical documentation

c) Custom-made devices do not require CE marking or conformity assessment by a Notified Body, whereas regular devices must undergo these processes

d) Both custom-made and regular devices require post-market surveillance, but custom-made devices are subject to less stringent reporting requirements

14. What should be provided in the technical documentation? (P.49)

a) Risk Management Documentation

b) Device Description and Specification

c) General Safety and Performance Requirements Checklist

d) Product Verification and Validation

e) All of the above

15. What is the purpose of clinical evaluation in technical documentation?

a) To facilitate regulatory clearance and provide marketing approval

b) To reduce production costs by identifying unnecessary design features

c) To specify and justify the level of clinical evidence required to demonstrate conformity with the general safety and performance requirements (GSPR)

d) To analyze market trends and identify similar products

e) Only required when the manufacturer has not performed, or does not possess, clinical investigation data for the device

16. What types of medical devices are required to undergo Clinical Evaluation?

a) All medical devices, regardless of risk classification

b) Only Class III and implantable devices

c) Only Class I devices with a measuring function

d) Only devices intended for clinical investigations

e) At manufacturer's discretion

17. Under the MDR, how long must manufacturers retain technical documentation for implantable devices? (Chapter II: Article 10: 8)

a) At least 10 years after the last device has been manufactured

b) At least 15 years after the last device has been manufactured

c) At least 15 years after the last device has been placed on the market

d) At least 20 years after the last device has been placed on the market

e) Perpetual

18. Which element is mandatory in a Risk Management Plan? (Annex II)

a) Supplier contracts

b) Marketing strategy

c) Benefit-risk analysis

d) Cost estimates

e) All of the above

19. How does the EU MDR require manufacturers to handle risks related to human factors?

a) Human factors are not considered in risk management under MDR

b) Risks related to human factors and usability must be specifically identified and addressed as part of the risk management process

c) Human factors risks are only relevant for Class III devices

d) Human factors risks are addressed only during clinical evaluations

e) Human factors risk are addressed solely by adding warning labels

20. Which of the following best describes the relationship between risk management and clinical evaluation for a medical device under the EU MDR?

a) Risk management and clinical evaluation are independent activities; clinical evidence is only needed for regulatory filing and does not affect the risk management file

b) Clinical evaluation is a subset of the risk management process and only focuses on device hazards identified after market launch

c) Clinical evaluation provides clinical evidence that informs the benefit-risk analysis, verifies the effectiveness of risk controls, identifies residual clinical risks and uncertainties, and guides PMCF and risk management actions

d) Risk management replaces the need for clinical evaluation when the device has no reported incidents

e) Clinical evaluation is only concerned with literature reviews and cannot be used to justify risk acceptability or design changes

21. What is the primary difference between clinical evaluation and clinical investigation?

a) A clinical evaluation involves new, systematic research on a device, while a clinical investigation is only an internal review of existing data

b) A clinical investigation is a planned, systematic study involving subjects to gather data on a device's clinical performance, whereas a clinical evaluation assesses existing data to demonstrate safety and performance

c) A clinical evaluation is optional for high-risk devices, while a clinical investigation is mandatory for all devices

d) A clinical investigation is conducted after market approval, while a clinical evaluation is only done during the initial device design phase

e) Both terms refer to the same process but are used interchangeably in the EU MDR

22. What is the maximum length of a Basic UDI-DI?

a) 23 characters

b) 24 characters

c) 25 characters

d) 26 characters

e) No limit

23. What is the primary purpose of the EU Basic Unique Device Identifier (UDI)?

a) To track the manufacturing costs of medical devices in the EU

b) To assign a unique code to each medical device for traceability and identification within the EU

c) To regulate the advertising standards for medical devices in the EU

d) To replace all existing barcodes on medical devices

e) To determine the certification validity period of a medical device

24. What is the primary difference between a UDI and a Basic UDI-DI under the EU MDR?

a) The UDI is only used for imported devices, while the Basic UDI-DI applies to all devices

b) The UDI uniquely identifies a specific device version and production unit, whereas the Basic UDI-DI serves as a single identifier for a group of devices with the same essential design and intended purpose

c) The UDI is assigned by the manufacturer, while the Basic UDI-DI is assigned by the notified body

d) The UDI is only required for Class III devices, while the Basic UDI-DI applies to Class I devices only

e) There is no difference; UDI and Basic UDI-DI are interchangeable terms

25. Where should the UDI be located? (Chapter II: Article 27,1)

a) On the label and packaging

b) On marketing materials

c) Only on the packaging box

d) Only in EUDAMED

e) Discretionary

26. Which device requires a UDI?

a) Only Notified Body certified devices

b) Only Class III devices

c) Only devices with implants

d) Only devices with electronic components

e) All medical devices placed on the EU market

27. Which of the following groups related to UDI Device Identifier (UDI-DI) and UDI Production Identifier (UDI-PI) is correct? (Chapter II: Article 27,1)

a) UDI-DI: a static, unique identifier for the specific model of a device

b) UDI-DI: includes production-related details like the expiration date

c) UDI-PI: a static, unique identifier for the specific model of a device

d) UDI-PI: indicating the entity responsible for manufacturing the device

e) They are the interchangeable

28. Under the EU Medical Device Regulation (MDR 2017/745), which product class(es) require(s) that a Periodic Safety Update Report (PSUR) be updated at least annually?

a) Class I devices only

b) Class IIa devices only

c) Class IIb and Class III devices

d) All device classes (Class I, IIa, IIb, III)

e) Implantable devices only

29. Under the EU Medical Device Regulation (MDR 2017/745), how often must a Periodic Safety Update Report (PSUR) be updated for a Class IIa medical device?

a) Every month

b) Every year

c) Every 2 years

d) Every 5 years

e) Only when a serious incident occurs

30. What should not be included in Periodic Safety Update Report (PSUR)?

a) Competitor analysis

b) Conclusion of the benefit-risk determination

c) Main findings of the Post-Market Clinical Follow-up (PMCF)

d) Volume of sales of the device

e) All of the above

31. What is the purpose of the General Safety and Performance Requirements (GSPR)?

a) To establish detailed requirements related to device labeling and packaging

b) To ensure that medical devices comply with general requirements related to safety, performance, design, manufacturing, and information provision

c) To replace the Unique Device Identifier (UDI)

d) To regulate the responsibilities of economic operators

e) To ensure conformance to common specifications

32. Under GSPR, how must manufacturers address the risk of infection and microbial contamination for medical devices?

a) By ensuring devices are disposable and single use

b) By including a mandatory antimicrobial coating on all devices

c) By limiting device's use to sterile environments only

d) By designing devices to minimize contamination risks and ensuring compatibility with sterilization processes

e) By defining the shelf life of the packaging

33. For which type of devices is a Summary of Safety and Clinical Performance (SSCP) required?

a) Class I devices

b) Class IIa devices

c) Class IIb (Implantable) and Class III devices

d) Class III devices only

e) All of the above

34. Which of the following should NOT be included in the SSCP?

a) Basic UDI-DI

b) Possible diagnostic or therapeutic alternatives

c) Suggested profile and training for users

d) Financial data about the manufacturing costs of the device

e) None of the above

35. What is the purpose of Post-market Surveillance (PMS)? (Chapter VII: Article 83: 2)

a) To monitor devices' quality, performance and safety after they have been released to the market

b) To monitor sales volumes and market share to inform future marketing strategies and product pricing

c) To gather user feedback exclusively for the purpose of product development and advertising

d) To evaluate the effectiveness of promotional campaigns and distributor performance

e) All of the above

36. What is the following key Content of a Post Market Surveillance Plan?

a) Device Performance and Safety Monitoring Parameters

b) Market Surveillance Date

c) Data Collection and Analysis Method

d) Risk/Benefit Analysis

e) All of the above

37. What is the main purpose of the Post-Market Clinical Follow-up (PMCF)?

a) To monitor the financial performance of the device in the market

b) To continuously update clinical data to confirm the safety and performance of the device throughout its lifecycle

c) To replace pre-market clinical evaluations for low-risk devices

d) To ensure compliance with ISO 13485 and other quality standards

e) All of the above

38. Which devices should not bear the CE marking? (Chapter II: Article 20: 1)

a) Class I devices

b) Class III devices

c) Investigational devices and custom-made devices

d) Non-implantable devices

e) Device without medical use

39. Which of the following best describes what a manufacturer must provide or demonstrate to obtain CE marking for a medical device under the EU MDR?

a) Only a Declaration of Conformity and a summary of product features

b) Complete Technical Documentation, a signed Declaration of Conformity, and, for higher-risk devices, successful completion of a conformity assessment by a Notified Body before affixing the CE mark

c) Product samples and a user manual

d) A quality certificate from any international standards organization

e) Foreign country approval

40. Which of the following is TRUE regarding the CE marking of software?

a) All software used in healthcare must have CE marking

b) Software developed and used exclusively within a healthcare institution always requires CE marking

c) CE marking is optional for low-risk medical device software

d) Only software classified as medical devices or accessories requires CE marking

e) All of the above

41. Where should the CE marking be located? (Chapter II: Article 20: 1)

a) On the device itself or its sterile packaging; in any instructions for use

b) On the device itself only

c) On its packaging only

d) Appear in any instructions for use only

e) On either the device or IFU

42. The quality management system (QMS) shall cover all parts and elements of a manufacturer's organization dealing with the quality of processes, procedures and devices. Which aspect is NOT explicitly mentioned as part of the QMS requirements? (Chapter II: Article 10: 9)

a) Risk management

b) Clinical evaluation

c) Marketing strategy

d) Product realization

e) Sales and Distribution

43. Which of the following are not included in the common safety and performance tests? (P.22)

a) Sterilization validation

b) Electrical safety

c) Biocompatibility

d) Transportation

e) Health condition of the users

44. When and to whom must a manufacturer notify about an anticipated interruption or discontinuation of supply of a device (other than a custom-made device), and under what conditions? (Chapter II: Article 10a: 1)

a) At least 6 months before, to the competent authority, economic operators, health institutions, and healthcare professionals, if the interruption could cause serious harm to patients or public health

b) At least 3 months before the interruption, only to the competent authority, regardless of potential harm

c) Immediately after the interruption, only if requested by the competent authority

d) Only if the interruption affects more than one Member State, to the European Commission

e) No notification is required

45. What key considerations must be addressed in the design and manufacture of medical devices?

a) Compatibility between the materials and biological tissues

b) The impact of processes on material properties

c) Toxicity of materials and substances used

d) All of the above

e) None of the above

46. If a serious incident involving a device occurs, how soon must the manufacturer report it to the competent authority under MDR? (Chapter VII: Article 87: 3)

a) Within 2 days after they became aware of the incident

b) Within 5 days after the manufacturer became aware of that threat

c) Within 10 days after they became aware of the incident

d) Within 15 days after they became aware of the incident

e) Within 30 days after they became aware of the incident

47. If a manufacturer becomes aware of a serious public health threat related to their device, how soon must they report it to the competent authority? (Chapter VII: Article 87: 4)

a) Within 2 days after the manufacturer became aware of that threat

b) Within 5 days after the manufacturer became aware of that threat

c) Within 10 days after the manufacturer became aware of that threat

d) Within 15 days after the manufacturer became aware of that threat

e) Within 30 days after the manufacturer became aware of that threat

48. Which of the following does NOT need to be done before launching medical devices on the market?

a) Technical documentation

b) CE marking

c) UDI

d) PSUR

e) Declaration of Conformity (DOC)

49. Which of the following should be contained in the instructions for use (IFU)?

a) The device's intended purpose

b) The performance characteristics of the device

c) Details of any preparatory treatment before it is ready for use

d) Precautions and Warning

e) All of the above

50. A manufacturer discovers a previously unknown risk associated with a device already on the market. What is the correct sequence of actions required?

a) Immediately recall all devices, notify users, and wait for regulatory guidance

b) Conduct a risk assessment, update the clinical evaluation, and then decide whether to notify authorities

c) Report the new risk to the competent authority, update the technical documentation and risk management file, inform users if necessary, and potentially implement corrective actions

d) Notify the notified body, update the device label, and conduct a new clinical investigation

e) Wait until the next scheduled post-market review before taking any action

Your score is

0%